SEATTLE--(BUSINESS WIRE)--Apr. 24, 2018--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the
appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an
experienced life sciences executive, currently serves as the Chief
Executive Officer of Flashlight Therapeutics.
“We are pleased to have Chris join Alpine’s Board of Directors during
this period of significant growth of our company,” said Mitchell H.
Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine.
“Chris’s strong track record of strategic and financial achievements,
including expertise supporting various corporate transactions, will add
value as we drive our two lead programs – ALPN-101 for
autoimmune/inflammatory diseases and ALPN-202 for immuno-oncology
indications – toward the clinic.”
Mr. Peetz previously served as Chief Financial Officer and Head of
Corporate Development at Tobira Therapeutics, a publicly-traded
biotechnology company acquired by Allergan in November 2016. Prior to
joining Tobira Therapeutics, he held senior management roles at Jennerex
Biotherapeutics and Onyx Pharmaceuticals (now Amgen), including
oversight of financial planning and corporate strategy. Prior to Onyx,
Mr. Peetz provided merger and acquisition advisory services at LaSalle
Corporate Finance, a part of ABN AMRO, and held positions at Abgenix and
Mr. Peetz holds a B.S.B.A. from Washington University in St. Louis and
an M.B.A. from the Stanford Graduate School of Business.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is focused on developing novel
protein-based immunotherapies using its proprietary Variant Ig Domain
(vIgD) technology. Our proprietary scientific platform is designed to
interact with multiple targets, including many present in the immune
synapse. Alpine’s vIgDs are developed using a process known as directed
evolution, which produces proteins capable of either enhancing or
diminishing an immune response and thereby may potentially apply
therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine
has also developed Transmembrane Immunomodulatory Protein (TIP)
technology, based on the vIgD technology, to potentially enhance
engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424005296/en/
Source: Alpine Immune Sciences, Inc.
Courtney Dugan, 212-257-6723